[1] KUYKENDALL A,DUPLOYEZ N,BOISSEL N,et al.Acute myeloid leukemia:the good,the bad,and the ugly[J].Am Soc Clin Oncol Educ Book,2018,38:555-573.
[2] 刘彦,克晓燕,王晶,等.伴FLT3-ITD突变的急性髓系白血病的临床特征和预后[J].中国实验血液学杂志,2018,26(2):354-358.
[3] 杨槟荧.FLT3-ITD和DNMT3A R882基因联合突变在急性髓系白血病中的研究进展[J].中国当代医药,2018,25(15):26-29.
[4] SAEVARSDOTTIR S,OLAFSDOTTIR T A,IVARSDOTTIR E V,et al.FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease[J].Nature,2020,584(7822):619-623.
[5] AUDIGER C,LESAGE S.FLT3 ligand is dispensable for the final stage of type 1 conventional dendritic cell differentiation[J].J Immunol,2020,128(32):111-119.
[6] TORT TARRÉS M,ASCHENBRENNER F,MAUS R,et al.The FMS-like tyrosine kinase-3 ligand/lung dendritic cell axis contributes to regulation of pulmonary fibrosis[J].Thorax,2019,74(10):947-957.
[7] TSAPOGAS P,MOONEY C J,BROWN G,et al.The cytokine Flt3-ligand in normal and malignant hematopoiesis[J].Int J Mol Sci,2017,18(6):1115.
[8] PETERLIN P,GASCHET J,GUILLAUME T,et al.FLT3 ligand plasma levels in acute myeloid leukemia[J].Haematologica,2019,104(6):e240-e243.
[9] O'DONNELL M R,TALLMAN M S,ABBOUD C N,et al.Acute myeloid leukemia,version 3.2017,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2017,15(7):926-957.
[10] KAYSER S,LEVIS M J.Clinical implications of molecular markers in acute myeloid leukemia[J].Eur J Haematol,2019,102(1):20-35.
[11] 张道玉,袁小青,颜晗,等.急性髓系白血病化疗效果和预后影响因素的研究进展[J].中南医学科学杂志,2015(4):457-463.
[12] 黄韵映,上官辉,汪包珍.化学法提取贮存骨髓涂片DNA检测Fms样酪氨酸激酶3基因突变预测急性髓系白血病患者预后[J].白血病·淋巴瘤,2017,26(5):272-275.
[13] KAINZ B,FONATSCH C,SCHWARZINGER I,et al.Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia[J].Haematologica,2015,90(5):695-696.
[14] ADNAN-AWAD S,GABER O,ELTOKHY S A,et al.FLT3-ITD mutations in egyptian patients of acute myeloid leukemia:correlation with cytogenetic, FAB subgroups and prognosis[J].Clin Lab,2017,63(5):1027-1034.
[15] HU X,CHEN F.Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia[J].Hematology,2019,24(1):651-660.
[16] 周萌,储小玲,薛胜利,等.FLT3抑制剂在急性髓系白血病中的研究进展[J].中华血液学杂志,2019,40(9):787-791.
[17] KAZI J U,RÖNNSTRAND L.FMS-like tyrosine kinase 3/FLT3:from basic science to clinical implications[J].Physiol Rev,2019,99(3):1433-1466.
[18] YUAN X,QIN X,WANG D,et al.Mesenchymal stem cell therapy induces FLT3L and CD1c(+) dendritic cells in systemic lupus erythematosus patients[J].Nat Commun,2019,10(1):2498.
[19] ZHOU C Z,WANG R F,CHENG D L,et al.FLT3/FLT3L-mediated CD103(+) dendritic cells alleviates hepatic ischemia-reperfusion injury in mice via activation of treg cells[J].Biomed Pharmacother,2019,118:109031.
[20] RAMOS M I,TAK P P,LEBRE M C.Fms-like tyrosine kinase 3 ligand-dependent dendritic cells in autoimmune inflammation[J].Autoimmun Rev,2014,13(2):117-124.
[21] THORNE A H,MALO K N,WONG A J,et al.Adjuvant screen identifies synthetic dna-encoding flt3l and cd80 immunotherapeutics as candidates for enhancing anti-tumor T cell responses[J].Front Immunol,2020,11:327.
[22] MILNE P,WILHELM-BENARTZI C,GRUNWALD M R,et al.Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia[J].Blood Adv,2019,3(20):3052-3061.
[23] CAO T,JIANG N,LIAO H,et al.The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia[J].Sci Rep,2019,9(1):12209.
[24] HUANG Y,HU J,LU T,et al.Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis[J].Cancer Manag Res,2019,11:4129-4142. |